問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site > 收納受試者人數排名

Search Result

List

107Cases

2015-09-16 - 2017-06-30

Phase III

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Condition/Disease

    Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Test Drug

    ABT-450/Ritonavir/ABT-267, ABT-333, Ribavirin

Participate Sites
6Sites

Terminated5Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2017-04-01 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

2016-11-01 - 2022-10-28

Phase III

A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer

  • Condition/Disease

    metastatic hormone-sensitive prostate cancer

  • Test Drug

    BAY 1841788/ODM-201(Darlutamide)

Participate Sites
8Sites

Recruiting6Sites

黃逸修
Taipei Veterans General Hospital

馮思中
Linkou Chang Gung Medical Foundation

2017-02-01 - 2019-05-09

Phase III

Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (EdoxabaN Treatment versus VKA in patients with AF undergoing PCI ( ENTRUST-AF PCI)

  • Condition/Disease

    Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement

  • Test Drug

    Edoxaban (DU-176b)

Participate Sites
13Sites

Terminated11Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2017-01-05 - 2019-12-31

Others

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

  • Condition/Disease

    Solid Tumors

  • Test Drug

    TECENTRIQ

Participate Sites
6Sites

Recruiting4Sites

Terminated1Sites

趙毅
Taipei Veterans General Hospital

陳仁熙
Linkou Chang Gung Medical Foundation

2018-07-24 - 2021-03-17

Phase III

A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Sotagliflozin

Participate Sites
8Sites

Terminated8Sites

江晨恩
Taipei Veterans General Hospital

2017-11-15 - 2022-12-31

Phase III

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Condition/Disease

    Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

  • Test Drug

    Sotagliflozin

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2015-11-01 - 2019-12-31

Phase III

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Bexagliflozin Tablets

Participate Sites
9Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2018-01-01 - 2022-12-31

Phase III

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Condition/Disease

    HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Test Drug

    Tesetaxel

Participate Sites
7Sites

Terminated7Sites

趙大中
Taipei Veterans General Hospital

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

2017-03-01 - 2019-12-31

Phase III

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

  • Condition/Disease

    Advanced or Metastatic Gastric Cancer

  • Test Drug

    Apatinib

Participate Sites
10Sites

Terminated8Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

1 4 5 6 7 8 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB